Preventive treatment for severe migraines
Part of Brain & nervous system, Pain clinical trials.
This study looks at how preventive treatments (botulinum toxin type A or anti-CGRP antibodies) affect thinking, memory, and quality of life in adults with hard-to-treat migraines. It aims to see if these treatments help more than just reducing headache days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have severe migraines that don't respond well to other treatments, with at least 8 migraine days per month
- Your doctor has recommended preventive treatment with botulinum toxin type A or a type of anti-CGRP medication (like eptinezumab)
- You can understand the study and give signed consent
- You do not have other neurological problems (like multiple sclerosis, stroke, or dementia), chronic pain conditions (like fibromyalgia), or severe hearing or vision loss
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the chemical changes in the blood of people with migraine. It aims to better understand the disease and may help find new treatments. You may qualify if you have episodic or chronic migraine and have not tried CGRP-targeting drugs.
This study looks at ways to help children and teens with migraine headaches by testing a care approach that includes access to evidence-based treatment. It may help if your child has frequent migraine headaches and is starting (or not already on) certain migraine-preventive medicines.
This study looks for new biological markers in people whose migraines don't respond to standard treatments. It aims to better understand why some migraines are hard to treat and may help guide future therapies.
This trial tests if Xeomin (a botulinum toxin injection) can help prevent chronic migraine. If you have frequent migraine headaches, you may be able to join.
This trial is testing new approaches for people whose migraines haven't improved with multiple preventive treatments. The goal is to find better options for those with hard-to-treat migraine.
This study tests a CGRP-blocking antibody to see how it affects migraine symptoms and the body’s automatic (involuntary) nerve functions. It may help people with migraine who have already tried several preventive medicines.
Hear when a new Chronic Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.